[Angiotensin-converting enzyme inhibitors after AMI].
The purpose of this study was to calculate the improvement in life expectancy by treating patients with left ventricular dysfunction after a myocardial infarction with an ACE inhibitor. Life expectancy was estimated as median lifetime and follow up in the TRACE study was prolonged until median lifetime could be calculated in both treatment groups. Median lifetime was reached in the placebo group after 4.6 years. In the trandolapril group median lifetime was increased by 15.3 months or 27% (7-51%). We conclude that the increase in lifetime by treatment of patients with left ventricular dysfunction after a myocardial infarction is substantial.
Torp-Pedersen
C T
CT
Kardiologisk afdeling P, Amtssygehuset i Gentofte. ctp@heart.dk
Køber
L
L
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D003718:Denmark / Q000453:epidemiology; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008017:Life Expectancy; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011379:Prognosis
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril